Skip to content
Axcess News – Lifestyle
Author:
ProMIS Neurosciences Inc.
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
November 17, 2026
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
November 12, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences in November
November 5, 2026
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
November 3, 2026
ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
October 6, 2026
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
September 1, 2026
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
August 13, 2026
Tortoise Capital Announces Correction to Previously Reported Net Asset Values for Tortoise Global Water ETF (TBLU)
August 6, 2026
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
August 3, 2026
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
July 28, 2026
1
2
Next Page
→